MedicalResearch

CHICAGO – A groundbreaking clinical trial presented at the American Association for Cancer Research (AACR) Annual Meeting 2025 has demonstrated that patients with advanced solid tumors experience significantly improved survival outcomes when treatment is tailored using information from both tissue and liquid biopsies. The findings from the phase II, multicenter ROME trial could redefine the approach to precision oncology and patient care.

At the prestigious American Association for Cancer Research (AACR) Annual Meeting 2025, researchers from The University of Texas MD Anderson Cancer Center unveiled promising results from several pioneering clinical trials that could redefine treatment paradigms across multiple cancer types. The presentations, covering personalized vaccines, metastasis-directed radiation therapy, and engineered exosome therapeutics, signal major advances in personalized oncology and immunotherapy.